Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar) injections less often while maintaining control of their disease. The main question it aims to answer is: can adalimumab/biosimilar injections be given less frequently without uveitis (eye inflammation) or arthritis (joint inflammation) returning? Researchers will compare adalimumab/biosimilar injection schedules of every 2 weeks, 4 weeks, 8 weeks, and 12 weeks to determine how injection frequency affects disease control. Participants will: * Take adalimumab/biosimilar injections every 2, 4, 8, or 12 weeks. * Attend study visits every 6 weeks over 24 weeks, with an additional follow-up visit at 48 weeks for checkups, tests, and questionnaires. * Keep a diary of how often they take adalimumab/biosimilar and other drugs they take for their uveitis/arthritis.

NCT Number	NCT07699107
Lead Sponsor	Nisha Acharya Collaborators: National Eye Institute (NEI), National Institutes of Health (NIH), University of California, San Francisco, University of California, Davis, University of California, Los Angeles, Children's Hospital Medical Center, Cincinnati, Children's Mercy Hospital Kansas City, University of Miami, University of Utah, University of Texas at Austin, Vanderbilt University Medical Center, University Hospitals Bristol and Weston NHS Foundation Trust, Alder Hey Children's NHS Foundation Trust, Great Ormond Street Hospital for Children NHS Foundation Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, Manchester University NHS Foundation Trust, Sheffield Children's NHS Foundation Trust, University Hospitals, Leicester, Meyer Children's Hospital IRCCS, Newcastle-upon-Tyne Hospitals NHS Trust, Moorfields Eye Hospital NHS Foundation Trust
Conditions	Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Enrollment	160 participants
Start Date	2026-09
Primary Completion	2030-05 (estimated)
Study Completion	2030-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-13